Moreover, we performed western blot to examine Bcl2 protein expression in three additional BRAF-mutant melanoma cell lines that were selected for resistance by treating with vemurafenib for about 40 days (a similar treatment time to the A375 study); and higher Bcl2 expression was observed in two of the three cell lines (Fig. 5i). Here, BRAF is linked to melanoma.